Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCND2 | P30279 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187962 | 0.96 | KDM4E (0.53) | KDM4EGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL248829 | 0.91 | MAPK1 (0.48) | KDM4EGAAHDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL1669811 | 0.89 | MAPK1 (0.47) | KDM4EGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL16039969 | 0.82 | MAPK8 (0.49) | HDAC3HDAC1HDAC2HDAC6MAPK1 | |
| SCHEMBL12125228 | 0.82 | GRM5 (0.49) | KDM4EGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL1256168 | 0.82 | MAPK1 (0.69) | KDM4EGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL4701457 | 0.82 | IGF1R (0.46) | KDM4EGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL1332209 | 0.82 | GRM5 (0.49) | KDM4EGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL16039970 | 0.82 | MAPK8 (0.49) | HDAC3HDAC1HDAC2HDAC6MAPK1 | |
| SCHEMBL1332208 | 0.82 | GRM5 (0.49) | KDM4EGAAHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119547-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11497738-B2 | Di-substituted pyrazole compounds for the treatment of diseases | FGH BIOTECH, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| EP-3448851-B1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH INC (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-109476635-B | Disubstituted pyrazoles for treatment of diseases | FGH生物科技公司 | 2021-07-13 | — | — | CN | disclosed |
| US-20190134017-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| WO-2017190086-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| US-8853420-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8853420-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20110263565-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263565-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2010012747-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263565-A1 | COMPOUNDS | MKI67, CCNA1, CCNT1 | KDM4E 1623/4885GAA 456/4885HDAC3 2084/4885 |
| US-20190134017-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | KDM4E 2648/4885GAA 928/4885HDAC3 142/4885 |
| US-20230119547-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | KDM4E 2648/4885GAA 928/4885HDAC3 142/4885 |
| US-11497738-B2 | Di-substituted pyrazole compounds for the treatment of diseases | SREBF1, SREBF2, CYP27A1 | KDM4E 2648/4885GAA 928/4885HDAC3 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.